Citadel Advisors
NEUP

Citadel Advisors’s Neuphoria Therapeutics NEUP Stock Holding History

Citadel Advisors’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$317K Buy
72,559
+53,228
+275% +$257K ﹤0.01% 10988
2026
Q1 		$78.7K Buy
+19,331
New +$81.7K ﹤0.01% 12187
2025
Q3 		– Sell
-14,606
Closed -$104K – 14502
2025
Q2 		$104K Buy
+14,606
New +$84.8K ﹤0.01% 11315

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

Citadel Advisors's NEUP Position: Q2 2026 in Review

Citadel Advisors increased its Neuphoria Therapeutics (NEUP) stake by 275% in Q2 2026, buying an estimated $257K and bringing the position to 72,559 shares worth $317K. The position accounts for ﹤0.01% of the portfolio, ranked #10988.

Citadel Advisors first reported a position in NEUP in Q2 2025 and has held it in 3 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • Citadel Advisors held 72,559 shares of Neuphoria Therapeutics worth $317K as of Q2 2026.
  • Citadel Advisors bought 53,228 Neuphoria Therapeutics shares in Q2 2026, an estimated $257K.
  • Neuphoria Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #10988 holding.
  • Citadel Advisors first reported a position in Neuphoria Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.